secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001628280-26-012264
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Solutions Q4 2025 rev $24.8M (+20% YoY), GAAP net income $2.1M; guides 2026 rev $112.5-$115M
--------------------------------------------------------------------------------

- Q4 revenue $24.8M (+20% YoY); full-year revenue $96.2M (+29% YoY).
- GAAP net income Q4 $2.1M ($0.04 EPS) vs net loss $1.2M; adjusted EBITDA $6.9M (28% of revenue).
- 2026 guidance: revenue $112.5M-$115.0M (17-20% growth), full-year GAAP net income expected.
- Biopreservation media in 16 approved CGT products; >70% share in Phase III CGT trials.
- Divested evo in Oct 2025 for $25.5M cash; cash & securities $120.2M at Dec 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000162828026012264/0001628280-26-012264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000162828026012264/blfs-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-012264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer